Analogic — Investor Presentation (March 2017)
38 slides from Analogic's investor presentation, Mar 15, 2017
Slide 1: Investor overview
Investor overview March 15, 2017 Exhibit 99.1
Slide 2: Safe Harbor
Safe Harbor Any statements about future expectations, plans, and prospects for the Company, including statements containing the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation
Slide 3: Use of Non-GAAP Financial Measures
This presentation includes non-GAAP financial measures that are not in accordance with, nor an alternative to, generally accepted accounting principles and may be different from such non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive se
Slide 4: Years of Imaging Innovation
50 Years of Imaging Innovation Founded in 1967 Advancing image guidance technology for medical and security Global research, engineering, and operations Fiscal 2016 Highlights: $509 million revenue $3.54 Non-GAAP* EPS Operating cash of $33 million, Free cash flow** of $20 million 1,500 employees wor
Slide 5: Our Imaging Technology Drives Innovative Products
Our Imaging Technology Drives Innovative Products Material Science Signal and image processing Precision A/D conversion Precision RF/Power Amplification Imaging & Guidance “Core Technologies” “Critical Imaging Chain” Mammo Ultrasound Probes High voltage power supplies High power amplifiers Pulsed RF
Slide 6: Our Business Segments
Our Business Segments Medical Imaging Ultrasound Security & Detection 57% of revenues* 32% of revenues* 11% of revenues* Increase content with OEMs Leverage common platforms Drive growth in emerging markets Focus in Urology and Surgery Expand into General Imaging with technology partner Exploit oppo
Slide 7: Moving to the Next Level of Performance
Moving to the Next Level of Performance Non-GAAP operating margin and non-GAAP EPS figures exclude certain charges; please refer to the non-GAAP reconciliation table in the back of this presentation. Inconsistent results in recent years requires renewed focus
Slide 8: Ultrasound
ULTRASOUND
Slide 9: FY2017 Ultrasound Restructuring
FY2017 Ultrasound Restructuring 90 day assessment of Ultrasound has been completed Objective Plan Resize expense structure to align with growth opportunities Define new Leadership structure in Ultrasound Consolidate R&D and service with closing of Vancouver Optimize manufacturing, sales, marketing a
Slide 10: Focused Ultrasound Market Opportunities
Focused Ultrasound Market Opportunities Global Ultrasound Market 2016 ($6.4 billion) 1 POC – Point of care 2 EMED: Emergency Medicine Revenue Growth Rate by Application (’15-’20) BK Ultrasound Markets ($0.6B) Partner Markets ($3B) Source: IHS 2016 Oncura Market ($0.2B) Technology Partnerships Focuse
Slide 11: Portfolio Optimization
Portfolio Optimization *Analogic Patented and Trademarked Technology Surgical Guidance bk5000 Urology bk3000 General Imaging Partnerships Point of Care Anesthesia/EMED Handheld and Vet bk3500 Portfolio Optimization
Slide 12: Ultrasound: Turnaround Opportunity
Ultrasound: Turnaround Opportunity Sales growth has not matched our pace of investment Focus on optimizing portfolio and improving operating profit FY17 and FY18 estimates are based on mid-point of range Non-GAAP operating margin and non-GAAP EPS figures exclude certain charges; please refer to the
Slide 13: Medical Imaging
Medical Imaging
Slide 14: Guidance in Medical Imaging
Guidance in Medical Imaging Computed Tomography Digital Mammography Magnetic Resonance
Slide 15: Increasing Value with Full Systems
Increasing Value with Full Systems Data Acquisition Subsystem Detection Management Subsystem Power & Data Management CT Imaging engine Image Reconfiguration GE OPTIMA NM/CT 640 Accuray TomoTherapy Anke 16-Slice CT
Slide 16: Ruggedized CT Gantry Installations
Qinghai Xinjiang Inner Mongolia Tibet Guizhou Zhejiang Fujian Gansu Ningxia Shanxi Shanxi Hebei Heilongjiang Jilin Liaoning Shandong Jiangsu Henan Anhui Hubei Hunan Jiangxi Yunnan Sichuan Chongqing Guangxi Guangdong Ruggedized CT Gantry Installations Beijing > 185 installed through Feb. 2017
Slide 17: Magnetic Resonance Power Sub-systems
Magnetic Resonance Power Sub-systems RF Amplifier Gradient Amplifier Enabled 3T wide bore systems Common platforms and modular design Design wins with new market entrants
Slide 18: Digital Mammography Detector Sub-Systems
Digital Mammography Detector Sub-Systems Analogic Enables Best Detection Superior Se Based Technology Premium 3D tomo performance Lower dose with best image quality Fastest Image acquisition US installed base of 2D is ~ 11,000 systems, more than 5000 are 7+ years Replacement cycle is moving to 3D
Slide 19: Medical Imaging: Solid Profitability
Medical Imaging: Solid Profitability OEM sourcing decisions effect short term revenue growth Margin improvement driven by product/customer mix and cost initiatives FY17 estimates are based on mid-point of range Non-GAAP operating margin and non-GAAP EPS figures exclude certain charges; please refer
Slide 20: Security and Detection
Security and Detection
Slide 21: Checked Baggage Opportunities with Leading OEMs
Checked Baggage Opportunities with Leading OEMs North America Replacement Demand 1800 sockets TSA extended EDS life from 10 to 15 years to prepare for next gen purchases Canada completing purchases of high-speed EDS systems Europe and Middle East Increasing Momentum 2000 sockets Early adoption under
Slide 22: Checkpoint CT Under Evaluation
Checkpoint CT Under Evaluation ConnectCT accepted into TSA laboratory for formal certification testing; International certification testing in early 2017 Commercial trials with CT in Europe validated a 2X operational improvement with over 1.3 million bags scanned while improving detection ConnectCT
Slide 23: Upside Potential in Rapid DNA
Upside Potential in Rapid DNA DNA profile generated in under 84 minutes vs. weeks in federal labs Significant market opportunity for law enforcement and government agencies FBI NDIS (National DNA Index System) approval achieved for domestic 4-color version Evaluation currently underway for new globa
Slide 24: Security and Detection: Strong Leverage
Security and Detection: Strong Leverage Revenue growth driven by international high speed tenders and upside with Checkpoint CT and RapidDNA Strong double digit revenue growth Mid-teens non-GAAP operating margins FY17 estimates are based on mid-point of range Non-GAAP operating margin and non-GAAP E
Slide 25: Financial Outlook
F SIPINANCIAL =. OUTLOOK
Slide 26: Financial Outlook
Financial Outlook FY17 - Expect flat revenue growth with non-GAAP operating margin between 10.0% and 11.5% resulting in non-GAAP diluted EPS of between $3.00 and $3.45 Fiscal 2018 - Total company revenues expected to be down low-single digits with Non-GAAP operating margins up approximately 1 point.
Slide 27: Strong Balance Sheet and Consistent Cash Flows
Strong Balance Sheet and Consistent Cash Flows 1 As of July 31, 2015 Includes $12MM tax refund $153M1 of cash/investments with no long term debt - YTD operating cash flow of $41M, Free cash flow of $35M Capital allocation through ongoing investment, M&A and share re-purchase $15 million share repurc
Slide 28: Appendix
Appendix OVERVIEW
Slide 29: Q2 FY17 Financial Highlights
Q2 FY17 Financial Highlights Strength in Security Offset by Ultrasound and Medical Imaging * Non-GAAP operating margin/income figures exclude certain charges; please refer to the non-GAAP reconciliation table in the back of this presentation and in Analogic’s Q2 FY 2017 earnings release available at
Slide 30: Revenue and Non-GAAP Operating Margin Trend
FY17 FY16 Revenue $M and Non-GAAP* Operating Margin Trend Non-GAAP Operating Margin* Non-GAAP OM 16% 21% 18% 20% 12% 20% GAAP OM 10% 16% 14% 17% 10% 17% 10% 9% 19% 16% 18% 15% 2% -2% 14% 11% 17% 9% FY17 FY16 -5% 7% -5% 4% -11% -2% -13% -23% -13% -2% -16% -11% Operating Performance by Segment Medical
Slide 31: Working Capital and Cash Flow
Working Capital and Cash Flow (Amounts may not foot due to rounding to millions) Operating cash flow of $14M in Q2, Cap Ex at $2M resulting in Free cash flow of $12M Accounts receivables lower driving DSO down by 3 days sequentially to 53 days Inventory down $2M sequentially on higher volume of ship
Slide 32: FY17 and Long Term Outlook
FY17 and Long Term Outlook FY17 - Expect flat revenue growth with non-GAAP operating margin between 10.0% and 11.5% resulting in non-GAAP diluted EPS of between $3.00 and $3.45 Ultrasound: Mid-single digits revenue declines with negative low-single digit op margin Restructuring actions will disrupt
Slide 33: Non-GAAP Reconciliation
Non-Gaap Reconciliation Gi \ OVERVIEW analogic” ‘
Slide 34: Non-GAAP Statements of Operations Reconciliation
NON-GAAP ST’ ME (hn thousands, excopt per share data) GAAP Income From Operation: Rost ‘Acquistion rolated revenues and expenses Non-GAAP Income From Operations Percentage of Total Net Revenue GAAP Other income (Expen: don BK Medical distrbutor mattor inquiry related costs ‘Acquisition rolated reven
Slide 35: Non-GAAP Statements of Operations Reconciliation
NON-GAAP STATEMENTS OF OPERATIONS RECONCILIATION (h thousands, except per share data) ‘Twelve months Ended July 34,2012 July 34,2013 July 31,2014 July 31,2015 July31, 2016 Medical Imaging GAAP Income From Operations Shore sation expense “ax refund related cha GAAP Income From Operations " Percentage
Slide 36: Non-GAAP Statement of Operations Reconciliation
Non-GAAP Statement of Operations Reconciliation (Amounts may not foot due to rounding to millions)
Slide 37: Non-GAAP Statement of Operations Reconciliation
Non-GAAP Statement of Operations Reconciliation (Amounts may not foot due to rounding to millions)
Slide 38: Non-GAAP Segment Financial Reconciliation
Non-GAAP Segment Financial Reconciliation (Amounts may not foot due to rounding to millions)